Andrew Cheng - Jun 30, 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President and CEO, Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Jun 30, 2025
Transactions value $
$21,243
Form type
4
Date filed
7/2/2025, 06:00 PM
Previous filing
Jun 20, 2025
Next filing
Jul 11, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cheng Andrew President and CEO, Director C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO /s/ Jonathan Young, Attorney-in-Fact 2025-07-02 0001778307

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Award $21.2K +890 +0.16% $23.87 551K Jun 30, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Dr. Cheng is voluntarily reporting the acquisition of these shares on June 30, 2025 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2 In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on January 2, 2025.